Immunome Raises $172.5M in Public Offering to Advance Targeted Cancer Therapies

Immunome, a biotechnology company focused on targeted cancer therapies, has closed an underwritten public offering of 22,258,064 shares of its common stock at $7.75 per share. The offering raised $172.5M in gross proceeds before deductions for underwriting discounts, commissions, and expenses. All shares were sold by Immunome.